SAN
DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that
members of the executive leadership team are scheduled to present
and host investor meetings at the following investor
conferences.
Details on the presentations are as follows:
|
Event:
|
|
|
|
Piper Sandler
36th Annual Healthcare Conference
|
|
Presenter:
|
|
|
|
Nicole LaBrosse, Chief
Financial Officer
|
|
Format:
|
|
|
|
Fireside Chat and 1x1
Meetings
|
|
Presentation
Date:
|
|
|
|
Wednesday, December 4,
2024
|
|
Presentation
Time:
|
|
|
|
10:30am PT / 1:30pm
ET
|
|
Location:
|
|
|
|
New York, NY
|
|
|
|
|
|
|
Event:
|
|
|
|
7th Annual
Evercore ISI HealthCONx Conference
|
|
Presenter:
|
|
|
|
Helen Torley, President
and Chief Executive Officer
|
|
Format:
|
|
|
|
Fireside Chat and 1x1
Meetings
|
|
Presentation
Date:
|
|
|
|
Wednesday, December 4,
2024
|
|
Presentation
Time:
|
|
|
|
9:30am PT / 12:30pm
ET
|
|
Location:
|
|
|
|
Miami, FL
|
|
|
|
|
|
A live audio webcast of the presentations will be available in
the Investor Relations section of the Company's website.
Replays of the audio webcasts will be available for 90 days
following the conference.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive
solutions to improve patient experiences and outcomes for emerging
and established therapies. As the innovators of ENHANZE® drug
delivery technology with the proprietary enzyme rHuPH20, Halozyme's
commercially-validated solution is used to facilitate the
subcutaneous delivery of injected drugs and fluids, with the goal
of improving the patient experience with rapid subcutaneous
delivery and reduced treatment burden. Having touched more than
800,000 patient lives in post-marketing use in eight commercialized
products across more than 100 global markets, Halozyme has licensed
its ENHANZE® technology to leading pharmaceutical and biotechnology
companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli
Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai
Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technologies that are designed to provide
commercial or functional advantages such as improved convenience,
reliability and tolerability, and enhanced patient comfort and
adherence. The Company has two commercial proprietary products,
Hylenex® and XYOSTED®, partnered commercial products and ongoing
product development programs with Teva Pharmaceuticals and Idorsia
Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
For more information visit www.halozyme.com and connect with us
on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-present-at-upcoming-investor-conferences-302317305.html
SOURCE Halozyme Therapeutics, Inc.
